Ann: Dronabinol Supply Agreement/Sleep Apnoea Trial Update, page-31

Correct. And this is exactly why the BOT MD believes they are undervalued at $150 million. And if their trials continue to be successful then he’s probably right.

But as an IHL shareholder we’re leveraged to four independent clinical trials which all have the potential to be company makers. And with a MC of only $25 million and generating revenue from the dental devices business this is one of the most exciting opportunities I’ve seen in a while.

If the sleep apnea clinical trials are successful IMO this could be a multi hundred million dollar company. A genuine OSA treatment that has potential to challenge the CPAP machine is worth how much? 500 million? More?

OSA is the big one for me but gum disease is also a very large global market and now that BOT are getting positive results with their trials on skin disease I’m happy to accept an argument that IHL have an improved chance of success in treating periodontitis (gum disease) through their clinical trials.